Development of therapeutic antibodies for the treatment of infection diseases and future aspect.
Drug Delivery System
; 37(5):378-387, 2022.
Article
in Japanese
| EMBASE | ID: covidwho-2262197
ABSTRACT
Since the late 1990 s, therapeutic antibodies have been developed for various oncology and immunoinflammatory diseases. To date, more than 100 therapeutic antibodies have been approved DDS in Japan, the U.S., and Europe for these indications. In contrast, the development of antibody drugs in the field of infectious diseases has been limited so far. The recent SARS-CoV-2 pandemic has highlighted the importance of therapeutic antibodies for infectious diseases as well as the development of drug delivery systems(DDS). This review summarizes the past development of antibody drugs for infectious diseases and provides a future perspective of how therapeutic antibodies can be developed by utilizing antibody engineering and DDS technologies.Copyright © 2022, Japan Society of Drug Delivery System. All rights reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Japanese
Journal:
Drug Delivery System
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS